Fig. 2From: INTERCEPT H3: a multicenter phase I peptide vaccine trial for the treatment of H3-mutated diffuse midline gliomasSummary of outcome measures of Intercept H3Primary outcome measures comprise of safety and immunogenicity. Secondary outcomes are the efficacy measures OS, PFS, their relation to H3K27M-specific T- and B- cells in blood and CSF as well as the relation between HLA type and immunogenicity. Translational research goals include the analysis of H3K27M presentation and mutation status in recurrent tumors as well as the T cell repertoire in recurrent tumors if reoperation or biopsy is clinically indicated and tissue is availableBack to article page